Why the study?
Understanding the pathways linking gut microbiota and host could enable the identification of metabolites as predictors for detecting incipient cardiovascular disease stages and potential therapeutic targets.
Design
Review
Answers are grounded in this paper and cite their sources.
Microbiota-targeted approaches merit exploration in CVD; leaves open causality and clinical utility pending interventional trials.
Gut microbiota, a term that includes microorganisms present in the gastrointestinal tract, has become very attractive lately due to its propensity to act as a virtual organ with endocrine functions, generating various bio-active metabolites, while playing an important role in human health and diseases, including cardiovascular diseases (CVDs). Focusing on the latter field, gastrointestinal dysbiosis that is the imbalance in the gut microbiota composition has been linked to various pathologies such as hypertension, atherosclerosis, myocardial infarction and heart failure. Several pathways were demonstrated to play a role in the complex and intertwined association between the gut microbiota and host, including metabolic endotoxemia, alteration of pattern recognition receptors and short-chain fatty acids, uremic toxins, bile acids and trimethylamine-N-oxide levels, leading to CVDs. Understanding these pathways can allow the identification of metabolites that could be useful predictors for detecting incipient CVDs stages and potential therapeutic targets. In this review, we summarize the pathways associating the gut microbiota with CVDs.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: